Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) CTO Sells 2,151 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) CTO Mark Plavsic sold 2,151 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total transaction of $16,670.25. Following the transaction, the chief technology officer now directly owns 209,456 shares of the company's stock, valued at approximately $1,623,284. This trade represents a 1.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Aura Biosciences Stock Performance

Shares of NASDAQ:AURA traded down $0.12 during trading on Friday, reaching $7.51. The stock had a trading volume of 146,728 shares, compared to its average volume of 138,951. Aura Biosciences, Inc. has a 1-year low of $6.63 and a 1-year high of $12.38. The stock has a market cap of $375.12 million, a PE ratio of -4.34 and a beta of 0.29. The business has a fifty day moving average price of $7.99 and a 200-day moving average price of $8.73.

Analyst Ratings Changes

AURA has been the topic of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of Aura Biosciences in a research report on Thursday, November 14th. Lifesci Capital upgraded Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $23.00.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in AURA. Long Focus Capital Management LLC raised its position in shares of Aura Biosciences by 123.9% in the fourth quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock valued at $20,861,000 after buying an additional 1,404,228 shares during the last quarter. Vanguard Group Inc. boosted its position in Aura Biosciences by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company's stock worth $15,764,000 after acquiring an additional 112,296 shares during the last quarter. Franklin Resources Inc. raised its holdings in Aura Biosciences by 3.2% in the 4th quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company's stock valued at $14,164,000 after acquiring an additional 54,103 shares during the last quarter. Levin Capital Strategies L.P. lifted its stake in Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock worth $10,255,000 after purchasing an additional 783,984 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company's stock worth $8,327,000 after purchasing an additional 3,972 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.